Skip to content

US · VERU · BIOTECHNOLOGY

Veru Inc. (VERU) intrinsic value and stock valuation

$1.94as of 2026-11-21 · Mkt cap 37.4M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Veru Inc. DCF and intrinsic value

InvestorsCraft values VERU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VERU’s statements →

Veru Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami, FL 33127 verupharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-22.73M
20112025
Free cash flow
-$-30.04M
20112025
Total equity
$18.3M-9.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$16.9M$16.3M$39.4M$61.3M
Operating income-$-24.75M-$-36.92M-$-93.78M-$-83.22M$13M
Net income-$-22.73M-$-37.8M-$-93.15M-$-83.78M$7.39M
EPSd-$-1.55M-$-2.8M-$-10.96M-$-10.46M$881.9K
Operating cash flow-$-30.04M-$-21.68M-$-88.01M-$-47.51M-$-15.57M
Capital expenditure-$0.00-$-160K-$-670K-$-730K-$-380K
Free cash flow-$-30.04M-$-21.84M-$-88.68M-$-48.24M-$-15.95M
Total assets$29.8M$60.4M$50M$135.4M$178.2M
Total debt$3.12M$13.9M$14.4M$15.9M$13.7M
Net debt-$-12.68M-$-11.05M$4.78M-$-64.31M-$-108.61M
Total equity$18.3M$32.3M$19.7M$82.8M$152.3M
Cash and short-term investments$18.3M$24.9M$9.63M$80.2M$122.4M
Income statement
20252024202320222021
Revenue$0.00$16.9M$16.3M$39.4M$61.3M
Cost of revenue$150K$11M$8.73M$8.76M$13.3M
Gross profit-$-150K$5.85M$7.57M$30.6M$47.9M
Research and development expenses$15.6M$12.8M$51.2M$70.7M$32.7M
Selling, general and administrative expenses$19.9M$31.2M$48.1M$43.2M$20.7M
Other expenses-$-10.78M-$-1.22M$2.09M$0.00$0.00
Operating expenses$24.8M$42.8M$101.4M$113.8M$53.4M
Cost and expenses$24.8M$53.8M$110.1M$122.6M$48.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$610K$2.43M$4.37M$4.89M
Depreciation and amortization$150K$270K$270K$210K$590K
Ebitda-$-35.38M-$-36.2M-$-89.98M-$-79.23M$9.75M
Operating income-$-24.75M-$-36.92M-$-93.78M-$-83.22M$13M
Total other income/expenses, net$9.07M-$-160K$1.11M-$-580K-$-8.71M
Income before tax-$-15.68M-$-37.08M-$-92.67M-$-83.8M$4.27M
Income tax expense$0.00$730K$480K$240K-$-3.13M
Net income-$-22.73M-$-37.8M-$-93.15M-$-83.78M$7.39M
Weighted average shares outstanding$14.7M$13.5M$8.5M$8.01M$7.63M
Weighted average diluted shares outstanding$14.7M$13.5M$8.5M$8.01M$8.38M
Balance sheet
20252024202320222021
Cash and short-term investments$18.3M$24.9M$9.63M$80.2M$122.4M
Net receivables$0.00$3.96M$4.51M$3.55M$13.8M
Inventory$0.00$4.14M$6.7M$8.62M$5.57M
Total current assets$18.9M$35.2M$22.9M$104M$151.8M
Property, plant and equipment, net$3.11M$4.85M$5.99M$5.97M$1.56M
Goodwill and intangible assets$6.88M$6.88M$6.88M$10.9M$10.9M
Long-term investments$0.00$0.00$0.00$0.00-$-1.56M
Total non-current assets$10.9M$25.2M$27.1M$31.4M$26.4M
Total assets$29.8M$60.4M$50M$135.4M$178.2M
Accounts payable$3.12M$3.04M$12.9M$22M$3.41M
Short-term debt$760K$2.09M$1.9M$2.13M$3.74M
Deferred revenue$0.00$400K$100K$0.00$130K
Total current liabilities$7.79M$11.9M$17.8M$38.7M$15.8M
Long-term debt$2.36M$11.8M$12.5M$13.8M$10M
Deferred revenue, non-current$0.00$0.00-$-450K$0.00$0.00
Total non-current liabilities$3.72M$16.2M$12.5M$13.9M$10.1M
Capital lease obligations$3.12M$3.99M$4.67M$5.05M$1.11M
Total liabilities$11.5M$28.1M$30.3M$52.6M$25.9M
Common stock$150K$1.49M$940K$830K$820K
Retained earnings-$-317.3M-$-294.57M-$-256.77M-$-163.62M-$-81.8M
Accumulated other comprehensive income (loss)$0.00-$-580K-$-580K-$-580K-$-580K
Total equity$18.3M$32.3M$19.7M$82.8M$152.3M
Total investments$2.53M$0.00$0.00$0.00-$-1.56M
Total debt$3.12M$13.9M$14.4M$15.9M$13.7M
Net debt-$-12.68M-$-11.05M$4.78M-$-64.31M-$-108.61M
Cash flow statement
20252024202320222021
Net income-$-22.73M-$-37.8M-$-93.15M-$-83.78M$7.39M
Depreciation and amortization$150K$270K$270K$210K$210K
Stock-based compensation$8.1M$13.6M$17.9M$11.2M$5.05M
Change in working capital-$-4.13M$220K-$-15.15M$25.9M-$-7.28M
Accounts receivable-$-660K$550K-$-4.15M$4.54M-$-3.56M
Inventory$860K$990K$650K-$-3.13M$550K
Accounts payable-$-2.76M-$-5.43M-$-7.43M$18.6M$600K
Net cash provided by operating activities-$-30.04M-$-21.68M-$-88.01M-$-47.51M-$-15.57M
Investments in property, plant and equipment-$0.00-$-160K-$-670K-$-730K-$-380K
Acquisitions, net$24.8M$0.00$0.00$5M$15M
Net cash used for investing activities$25.1M$150K$6.33M$4.27M$14.6M
Common stock issued$0.00$35.3M$6.01M$1.08M$108.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.22M$36.8M$11.1M$1.07M$109.7M
Net change in cash-$-9.12M$15.3M-$-70.57M-$-42.17M$108.8M
Cash at end of period$15.8M$24.9M$9.63M$80.2M$122.4M
Operating cash flow-$-30.04M-$-21.68M-$-88.01M-$-47.51M-$-15.57M
Capital expenditure-$0.00-$-160K-$-670K-$-730K-$-380K
Free cash flow-$-30.04M-$-21.84M-$-88.68M-$-48.24M-$-15.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Veru Inc.

        Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

        CEO
        Mitchell S. Steiner
        Employees
        20
        Beta
        -1.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Veru Inc. (VERU)?

        InvestorsCraft does not currently publish an intrinsic value for VERU. How the IC value is calculated.

        Is VERU undervalued?

        InvestorsCraft does not publish an undervaluation signal for VERU at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.